share_log

Eli Lilly Announced Topline Results From The SURMOUNT-5 Phase 3b Open-label Randomized Clinical Trial

Benzinga ·  Dec 4, 2024 19:46
Eli Lilly Announced Topline Results From The SURMOUNT-5 Phase 3b Open-label Randomized Clinical Trial
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment